See more : Xinyuan Real Estate Co., Ltd. (XIN) Income Statement Analysis – Financial Results
Complete financial analysis of Nippon Chemiphar Co., Ltd. (4539.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nippon Chemiphar Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- ikeGPS Group Limited (IKE.NZ) Income Statement Analysis – Financial Results
- Asian American Medical Group Limited (AJJ.AX) Income Statement Analysis – Financial Results
- SCVX Corp. (SCVX-UN) Income Statement Analysis – Financial Results
- Victorian Plumbing Group plc (VIC.L) Income Statement Analysis – Financial Results
- The Dixie Group, Inc. (DXYN) Income Statement Analysis – Financial Results
Nippon Chemiphar Co., Ltd. (4539.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.chemiphar.co.jp
About Nippon Chemiphar Co., Ltd.
Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.75B | 31.56B | 32.51B | 31.54B | 31.76B | 34.18B | 35.33B | 35.69B | 35.60B | 35.12B | 31.89B | 31.94B | 28.51B | 27.36B | 23.98B | 22.31B | 20.92B |
| Cost of Revenue | 23.01B | 23.37B | 23.43B | 20.10B | 19.20B | 19.66B | 19.54B | 19.45B | 18.80B | 18.35B | 15.13B | 14.92B | 12.87B | 12.99B | 11.45B | 10.39B | 8.78B |
| Gross Profit | 7.74B | 8.19B | 9.07B | 11.44B | 12.56B | 14.53B | 15.80B | 16.24B | 16.80B | 16.76B | 16.77B | 17.02B | 15.64B | 14.37B | 12.53B | 11.92B | 12.14B |
| Gross Profit Ratio | 25.17% | 25.94% | 27.91% | 36.28% | 39.53% | 42.50% | 44.71% | 45.51% | 47.18% | 47.74% | 52.57% | 53.29% | 54.86% | 52.52% | 52.26% | 53.44% | 58.03% |
| Research & Development | 2.33B | 2.42B | 2.39B | 2.00B | 2.17B | 2.07B | 2.28B | 1.98B | 1.89B | 1.76B | 1.67B | 1.94B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.83B | 5.94B | 5.79B | 5.82B | 6.86B | 7.58B | 13.95B | 7.26B | 6.25B | 6.33B | 7.39B | 7.28B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 76.00M | 64.00M | 66.00M | 3.06B | 3.16B | 3.42B | 4.13B | 4.16B | 5.52B | 5.40B | 4.38B | 3.93B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.91B | 6.01B | 5.86B | 8.88B | 10.02B | 11.00B | 13.95B | 11.42B | 11.76B | 11.73B | 11.77B | 11.21B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | -33.00M | -105.00M | 63.00M | 38.00M | 10.00M | 14.00M | 113.00M | 16.00M | 73.00M | 41.00M | 2.00M | 44.00M | 20.00M | -40.00M | -145.00M | -113.00M |
| Operating Expenses | 8.23B | 8.43B | 8.25B | 10.88B | 12.19B | 13.06B | 13.95B | 13.40B | 13.65B | 13.48B | 13.44B | 13.15B | 12.72B | 12.37B | 11.77B | 11.34B | 10.97B |
| Cost & Expenses | 31.24B | 31.80B | 31.68B | 30.98B | 31.39B | 32.72B | 33.48B | 32.85B | 32.46B | 31.83B | 28.57B | 28.07B | 25.59B | 25.36B | 23.22B | 21.73B | 19.75B |
| Interest Income | 3.00M | 2.00M | 89.00M | 1.00M | 72.00M | 78.00M | 1.00M | 0.00 | 13.00M | 3.00M | 0.00 | 1.00M | 2.00M | 4.00M | 4.00M | 10.00M | 19.00M |
| Interest Expense | 150.00M | 122.00M | 118.00M | 122.00M | 124.00M | 129.00M | 133.00M | 136.00M | 152.00M | 158.00M | 172.00M | 179.00M | 205.00M | 212.00M | 206.00M | 132.00M | 115.00M |
| Depreciation & Amortization | 1.46B | 1.50B | 1.59B | 1.39B | 1.27B | 1.35B | 1.19B | 1.11B | 1.20B | 1.35B | 1.04B | 1.01B | 920.00M | 927.00M | 717.00M | 580.00M | 282.00M |
| EBITDA | 1.40B | 1.26B | 2.41B | 1.96B | 1.64B | 2.81B | 3.04B | 3.95B | 4.30B | 8.16B | 4.26B | 4.79B | 3.82B | 2.55B | 1.48B | 1.21B | 1.32B |
| EBITDA Ratio | 4.56% | 5.33% | 8.38% | 6.65% | 5.36% | 8.74% | 8.55% | 11.48% | 12.07% | 13.46% | 13.83% | 15.35% | 13.67% | 10.79% | 6.30% | 4.81% | 6.72% |
| Operating Income | -494.00M | -241.00M | 825.00M | 564.00M | 364.00M | 1.46B | 1.85B | 2.84B | 3.15B | 3.29B | 3.33B | 3.87B | 2.92B | 2.00B | 767.00M | 580.00M | 1.17B |
| Operating Income Ratio | -1.61% | -0.76% | 2.54% | 1.79% | 1.15% | 4.28% | 5.23% | 7.95% | 8.83% | 9.35% | 10.43% | 12.12% | 10.25% | 7.31% | 3.20% | 2.60% | 5.59% |
| Total Other Income/Expenses | 292.00M | 721.00M | 151.00M | 149.00M | 368.00M | -10.00M | -71.00M | 13.00M | -200.00M | -192.00M | -272.00M | -271.00M | -225.00M | -584.00M | -210.00M | -83.00M | -253.00M |
| Income Before Tax | -202.00M | 480.00M | 976.00M | 713.00M | 732.00M | 1.45B | 1.78B | 2.85B | 2.95B | 3.09B | 3.06B | 3.60B | 2.70B | 1.42B | 557.00M | 497.00M | 917.00M |
| Income Before Tax Ratio | -0.66% | 1.52% | 3.00% | 2.26% | 2.31% | 4.25% | 5.03% | 7.98% | 8.27% | 8.81% | 9.58% | 11.28% | 9.46% | 5.17% | 2.32% | 2.23% | 4.38% |
| Income Tax Expense | -21.00M | 141.00M | 275.00M | 218.00M | 296.00M | 572.00M | 617.00M | 795.00M | 984.00M | 1.19B | 1.17B | 1.48B | 1.26B | 762.00M | 267.00M | 329.00M | 527.00M |
| Net Income | -180.00M | 339.00M | 700.00M | 495.00M | 436.00M | 881.00M | 1.16B | 2.05B | 1.96B | 1.90B | 1.89B | 2.13B | 1.44B | 573.00M | 270.00M | 168.00M | 390.00M |
| Net Income Ratio | -0.59% | 1.07% | 2.15% | 1.57% | 1.37% | 2.58% | 3.28% | 5.76% | 5.51% | 5.41% | 5.92% | 6.65% | 5.05% | 2.09% | 1.13% | 0.75% | 1.86% |
| EPS | -49.88 | 93.92 | 194.09 | 137.69 | 121.28 | 245.04 | 315.15 | 529.92 | 499.01 | 474.35 | 461.91 | 517.59 | 346.04 | 139.44 | 70.82 | 44.05 | 102.20 |
| EPS Diluted | -49.88 | 93.92 | 194.09 | 137.69 | 121.28 | 245.04 | 315.15 | 529.91 | 498.82 | 474.20 | 461.70 | 517.50 | 346.04 | 139.44 | 70.82 | 44.05 | 102.20 |
| Weighted Avg Shares Out | 3.61M | 3.61M | 3.61M | 3.59M | 3.60M | 3.60M | 3.68M | 3.88M | 3.93M | 4.00M | 4.09M | 4.11M | 4.16M | 4.11M | 3.81M | 3.81M | 3.82M |
| Weighted Avg Shares Out (Dil) | 3.61M | 3.61M | 3.61M | 3.59M | 3.60M | 3.60M | 3.68M | 3.88M | 3.93M | 4.00M | 4.09M | 4.11M | 4.16M | 4.11M | 3.81M | 3.81M | 3.82M |
Source: https://incomestatements.info
Category: Stock Reports